Investor Relations
Corporate Profile
Selecta Biosciences Inc. founded in 2008, is leveraging its clinically-validated ImmTORTM platform to develop antigen-specific tolerogenic therapies. With a proven ability to induce tolerance to highly immunogenic molecules, ImmTOR can be leveraged to both amplify the efficacy of biologics, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases.
